• 1
    Sedgh G, Singh S, Shah IH, Ahman E, Henshaw SK, Bankole A. Induced TOP: incidence and trends worldwide from 1995 to 2008. Lancet 2012;379:62532.
  • 2
    Fulton BD, Scheffler RM, Sparkes SP, Auh EY, Vujicic M, Soucat A. Health workforce skill mix and task shifting in low income countries: a review of recent evidence. Hum Resour Health 2011;9:1.
  • 3
    Pereira C, Bugalho A, Bergstrom S, Vaz F, Cotiro M. A comparative study of caesarean deliveries by assistant medical officers and obstetricians in Mozambique. Br J Obstet Gynaecol 1996;103:50812.
  • 4
    Gessessew A, Barnabas GA, Prata N, Weidert K. Task shifting and sharing in Tigray, Ethiopia, to achieve comprehensive emergency obstetric care. Int J Gynaecol Obstet 2011;113:2831.
  • 5
    Fetters T, Tesfaye S, Clark KA. An assessment of postTOP care in three regions in Ethiopia, 2000 to 2004. Int J Gynaecol Obstet 2008;101:1006.
  • 6
    Warriner IK, Wang D, Huong NT, Thapa K, Tamang A, Shah I, et al. Can midlevel health-care providers administer early medical TOP as safely and effectively as doctors? A randomised controlled equivalence trial in Nepal. Lancet 2011;377:115561.
  • 7
    Warriner IK, Meirik O, Hoffman M, Morroni C, Harries J, My Huong NT, et al. Rates of complication in first-trimester manual vacuum aspiration TOP done by doctors and mid-level providers in South Africa and Vietnam: a randomised controlled equivalence trial. Lancet 2006;368:196572.
  • 8
    Afable-Munsuz A, Gould H, Stewart F, Phillips KA, Van Bebber SL, Moore C. Provider practice models for and costs of delivering medication TOP – evidence from 11 US TOP care settings. Contraception 2007;75:4551.
  • 9
    Ashok PW, Templeton A, Wagaarachchi PT, Flett GM. Factors affecting the outcome of early medical TOP: a review of 4132 consecutive cases. BJOG 2002;109:12819.
  • 10
    Fiala C, Winikoff B, Helstrom L, Hellborg M, Gemzell-Danielsson K. Acceptability of home-use of misoprostol in medical TOP. Contraception 2004;70:38792.
  • 11
    Kopp Kallner H, Fiala C, Stephansson O, Gemzell-Danielsson K. Home self-administration of vaginal misoprostol for medical TOP at 50-63 days compared with gestation of below 50 days. Hum Reprod 2010;25:11537.
  • 12
    Spiegelman D, Hertzmark E. Easy SAS calculations for risk or prevalence ratios and differences. Am J Epidemiol 2005;162:199200.
  • 13
    Piaggio G, Elbourne DR, Altman DG, Pocock SJ, Evans SJ. Reporting of noninferiority and equivalence randomized trials: an extension of the CONSORT statement. JAMA 2006; 295:115260.
  • 14
    Rose SB, Lawton BA. Impact of long-acting reversible contraception on return for repeat TOP. Am J Obstet Gynecol 2012; 206:37.e16.
  • 15
    Cameron ST, Glasier A, Dewart H, Johnstone A, Burnside A. Telephone follow-up and self-performed urine pregnancy testing after early medical TOP: a service evaluation. Contraception 2012;86:6773.
  • 16
    Aubeny E, Peyron R, Turpin CL, Renault M, Targosz V, Silvestre L, et al. Termination of early pregnancy (up to 63 days of amenorrhea) with mifepristone and increasing doses of misoprostol [corrected]. Int J Fertil Menopausal Stud 1995;40(Suppl 2):8591.
  • 17
    Peyron R, Aubeny E, Targosz V, Silvestre L, Renault M, Elkik F, et al. Early termination of pregnancy with mifepristone (RU 486) and the orally active prostaglandin misoprostol. N Engl J Med 1993;328:150913.
  • 18
    Elul B, Hajri S, Ngoc NN, Ellertson C, Slama CB, Pearlman E, et al. Can women in less-developed countries use a simplified medical TOP regimen? Lancet 2001;357:14025.